Back to top
more

Infinity Pharmaceuticals, Inc. (INFI)

(Delayed Data from NSDQ)

$1.71 USD

1.71
99,328

+0.06 (3.64%)

Updated May 3, 2019 04:00 PM ET

After-Market: $1.72 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

WellCare and Catholic Health Team Up to Improve Health Care

WellCare of New York, Inc., a wholly owned subsidiary of WellCare Health Plans, Inc. (WCG), recently inked a deal with Catholic Health and Catholic Medical Partners to enhance its health care services.

    Community Health Completes Tender Offer for Senior Notes

    Community Health Systems, Inc. (CYH) recently announced the completion of the previously announced cash tender offer for its outstanding 5.125% Senior Secured Notes, due 2018.

      What Makes Valeant Pharmaceuticals (VRX) a Strong Sell?

      Valeant Pharmaceuticals (VRX) has witnessed a significant price decline in the past four weeks, and it has lately seen negative earnings estimate revisions as well.

        Should You Get Rid of Patheon (PTHN) Now?

        Patheon (PTHN) is one stock you should avoid as it has seen a significant price decline and negative earnings estimate revisions.

          What Makes Tesaro (TSRO) a Strong Sell?

          Tesaro (TSRO) is one stock you should avoid as it has seen a significant price decline and negative earnings estimate revisions.

            Are Options Traders Betting on a Big Move in Infinity Pharmaceuticals (INFI) Stock?

            Investors in Infinity Pharmaceuticals, Inc. (INFI) need to pay close attention to the stock based on moves in the options market lately.

              3 Reasons Why Infinity Pharmaceuticals (INFI) is a Great Momentum Stock

              If you are looking for a fresh pick that has potential to move in the right direction, definitely keep Infinity Pharmaceuticals (INFI) on your short list as this looks be a stock that is very well-positioned to soar in the near term.

                Infinity Pharma Focuses on Cancer Drug: Competition Looms

                We issued an updated research report on Infinity Pharmaceuticals, Inc. (INFI) on Mar 20, 2017.

                  Infinity (INFI) Reports Narrower-than-Expected Loss in Q4

                  Infinity Pharmaceuticals, Inc. (INFI) reported a loss of 46 cents per share in fourth-quarter 2016, much narrower than the Zacks Consensus Estimate loss of 63 cents.

                    Infinity Pharmaceuticals (INFI) Catches Eye: Stock Up 13.5%

                    Infinity Pharmaceuticals, Inc. (INFI) saw its shares rise almost 7% in the last trading session.

                      Not Too Late to Ride on Q4 Earnings: 3 Biotech Picks

                      The biotech sector continues to witness a flurry of mergers and acquisitions and licensing deals.